Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier

Annual Review of Pharmacology and Toxicology

Volumn 55, Issue , 2015, Pages 613-631

  Lajoie, Jason M ^a   Shusta, Eric V ^a  

^a University of Wisconsin Madison   (United States)

Author keywords

Antibody; Biologics; Blood brain barrier; Insulin receptor; Low density lipoprotein receptor; Receptor mediated transport; Transferrin receptor

Indexed keywords

ANTIBODY; BIOLOGICAL PRODUCT; FC5 ANTIBODY; INSULIN RECEPTOR; LIGAND; LOW DENSITY LIPOPROTEIN RECEPTOR; RABIES VIRUS GLYCOPROTEIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; CELL SURFACE RECEPTOR; DRUG CARRIER;

ACTIVE TRANSPORT; BLOOD BRAIN BARRIER; BRAIN; BRAIN CELL; CELL MEMBRANE; DRUG DELIVERY SYSTEM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TRANSPORT; HUMAN; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR MEDIATED TRANSPORT; REVIEW; TRANSCYTOSIS; ANIMAL; CAPILLARY PERMEABILITY; CHEMISTRY; MEDICINAL CHEMISTRY; METABOLISM; PHARMACEUTICS; PROCEDURES; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL PRODUCTS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HUMANS; RECEPTORS, CELL SURFACE; TECHNOLOGY, PHARMACEUTICAL;

EID: 84920768217     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010814-124852     Document Type: Review

References (125)

1. Pardridge WM. 2005. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2:3-14
2. Correale J, Villa A. 2009. Cellular elements of the blood-brain barrier. Neurochem. Res. 34:2067-77
3. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. 2010. Structure and function of the blood-brain barrier. Neurobiol. Dis. 37:13-25
4. Hartz AMS, Bauer B. 2011. ABC transporters in the CNS-an inventory. Curr. Pharm. Biotechnol. 12(4):656-73
5. Daneman R. 2012. The blood-brain barrier in health and disease. Ann. Neurol. 72(5):648-72
6. Pardridge WM. 2008. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug. Chem. 19(7):1327-38
7. Pardridge WM. 2007. Blood-brain barrier delivery. Drug Discov. Today 12:54-61
8. Ohtsuki S, Terasaki T. 2007. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm. Res. 24(9):1745-58
9. Gynther M, Laine K, Ropponen J, Leppanen J, Mannila A, et al. 2008. Large neutral amino acid transporter enables brain drug delivery via prodrugs. J. Med. Chem. 51:932-36
10. Begley DJ. 2004. ABC transporters and the blood-brain barrier. Curr. Pharm. Des. 10:1295-312
11. Hartz AMS, Miller DS, Bauer B. 2010. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-βin a mouse model of Alzheimers disease. Mol. Pharmacol. 77(5):715-23
12. Kumagai AK, Eisenberg JB, Pardridge WM. 1987. Absorptive-mediated endocytosis of cationized albumin and a β-endorphin-cationized albumin chimeric peptide by isolated brain capillaries: model system of blood-brain barrier transport. J. Biol. Chem. 262(31):15214-19
13. Poduslo JF, Curran GL. 1996. Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers. J. Neurochem. 66(4):1599-609
14. Poduslo JF, Curran GL, Gill JS. 1998. Putrescine-modified nerve growth factor: bioactivity, plasma pharmacokinetics, blood-brain/nerve barrier permeability, and nervous system biodistribution. J. Neurochem. 71(4):1651-60
15. Herve F, Ghinea N, Scherrmann J-M. 2008. CNS delivery via adsorptive transcytosis. AAPS J. 10(3):455-72
16. Descamps L, Dehouck MP, Torpier G, Cecchelli R. 1996. Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells. Am. J. Physiol. 270(4 Pt. 2):H1149-58
17. Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G, Cecchelli R. 1997. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J. Cell Biol. 138(4):877-89
18. Duffy KR, Pardridge WM. 1987. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res. 420(1):32-38
19. Golden PL, Maccagnan TJ, Pardridge WM. 1997. Human blood-brain barrier leptin receptor: binding and endocytosis in isolated human brain microvessels. J. Clin. Investig. 99(1):14-18
20. Parkar NS, Akpa BS, Nitsche LC, Wedgewood LE, Place AT, et al. 2009. Vesicle formation and endocytosis: function, machinery, mechanisms, and modeling. Antioxid. Redox Signal. 11(6):1301-12
21. Rodriguez-Boulan E, Kreitzer G, M usch A. 2005. Organization of vesicular trafficking in epithelia. Nat. Rev. Mol. Cell Biol. 6(3):233-47
22. Brooks DA. 2009. The endosomal network. Int. J. Clin. Pharmacol. Ther. 47(Suppl. 1):S9-17
23. Strazielle N, Ghersi-Egea JF. 2013. Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules. Mol. Pharm. 10(5):1473-91
24. Candela P, Gosselet F, Miller F, Buee-Scherrer V, Torpier G, et al. 2008. Physiological pathway for low-density lipoproteins across the blood-brain barrier: transcytosis through brain capillary endothelial cells in vitro. Endothelium 15(5-6):254-64
25. Chung NS, Wasan KM. 2004. Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv. Drug Deliv. Rev. 56(9):1315-34
26. Friden PM, Walus LR, Musso GF, Taylor MA, Malfroy B, Starzyk RM. 1991. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc. Natl. Acad. Sci. USA 88(11):4771-75
27. Pardridge WM, Buciak JL, Friden PM. 1991. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J. Pharmacol. Exp. Ther. 259(1):66-70
28. Broadwell RD, Baker-Cairns BJ, Friden PM, Oliver C, Villegas JC. 1996. Transcytosis of protein through the mammalian cerebral epithelium and endothelium: III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor. Exp. Neurol. 142:47-65
29. Jones AR, Shusta EV. 2007. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm. Res. 24:1759-71
30. Lu JZ, Hui EK-W, Boado RJ, Pardridge WM. 2010. Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase. Bioconjug. Chem. 21(1):151-56
31. Gabathuler R. 2010. Development of new peptide vectors for the transport of therapeutic across the blood-brain barrier. Ther. Deliv. 1(4):571-86
32. Daneman R, Zhou L, Agalliu D, Cahoy JD, Kaushal A, Barres BA. 2010. The mouse blood-brain barrier transcriptome: A new resource for understanding the development and function of brain endothelial cells. PLOS ONE 5(10):e13741
33. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, et al. 2011. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem. 117:333-45
34. Moos T, Morgan EH. 2000. Transferrin and transferrin receptor function in brain barrier systems. Cell. Mol. Neurobiol. 20(1):77-95
35. Sharma G, Modgil A, Layek B, Arora K, Sun C, et al. 2013. Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: biodistribution and transfection. J. Control. Release 167(1):1-10
36. Staquicini FI, Ozawa MG, Moya CA, Driessen WHP, Barbu EM, et al. 2011. Systemic combinatorial peptide selection yields a non-canonical iron-mimicrymechanism for targeting tumors in amousemodel of human glioblastoma. J. Clin. Investig. 121(1):161-73
37. Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, et al. 2006. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 125(2):385-98
38. Hajitou A, Rangel R, Trepel M, Soghomonyan S, Gelovani JG, et al. 2007. Design and construction of targeted AAVP vectors for mammalian cell transduction. Nat. Protoc. 2(3):523-31
39. Qian ZM, Li HY, Sun HZ, Ho K. 2002. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 54:561-87
40. Boado RJ, Zhang Y, Wang Y, Pardridge WM. 2009. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol. Bioeng. 102(4):1251-58
41. Sumbria RK, Zhou Q-H, Hui EK-W, Lu JZ, Boado RJ, Pardridge WM. 2013. Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice. Mol. Pharm. 10(4):1425-31
42. Zhou Q-H, Boado RJ, Hui EK-W, Lu JZ, Pardridge WM. 2011. Brain-penetrating tumor necrosis factor decoy receptor in the mouse. Drug Metab. Dispos. 39(1):71-76
43. Zhou Q-H, Sumbria R, Hui EK-W, Lu JZ, Boado RJ, Pardridge WM. 2011. Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor. J. Pharmacol. Exp. Ther. 339(2):618-23
44. Zhou Q-H, Hui EK-W, Lu JZ, Boado RJ, Pardridge WM. 2011. Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinsons disease in the mouse. Brain Res. 1382:315-20
45. Fu A, Zhou Q-H, Hui EK-W, Lu JZ, Boado RJ, Pardridge WM. 2010. Intravenous treatment of experimental Parkinsons disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier. Brain Res. 1352:208-13
46. Zhang Y, Pardridge WM. 2009. Near complete rescue of experimental Parkinsons disease with intravenous, non-viral GDNF gene therapy. Pharm. Res. 26(5):1059-63
47. Boado RJ, Zhou Q-H, Lu JZ, Hui EK-W, Pardridge WM. 2010. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol. Pharm. 7(1):237-44
48. Sumbria RK, Hui EK-W, Lu JZ, Boado RJ, Pardridge WM. 2013. Disaggregation of amyloid plaque in brain of Alzheimers disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide. Mol. Pharm. 10(9):3507-13
49. Zhou Q-H, Fu A, Boado RJ, Hui EK-W, Lu JZ, Pardridge WM. 2011. Receptor-mediated Abeta amyloid antibody targeting to Alzheimers disease mouse brain. Mol. Pharm. 8(1):280-85
50. Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, et al. 2014. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81(1):49-60
51. Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, et al. 2011. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med. 3(84):84ra44
52. Couch JA, Yu YJ, Zhang Y, Tarrant JM, Fuji RN, et al. 2013. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci. Transl. Med. 5(183):183ra57
53. Bien-Ly N, Yu YJ, Bumbaca D, Elstrott J, Boswell CA, et al. 2014. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J. Exp. Med. 211(2):233-44
54. Lee HJ, Engelhardt B, Lesley J, Bickel U, Pardridge WM. 2000. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J. Pharmacol. Exp. Ther. 292:1048-52
55. Zhang Y, Wang Y, Boado RJ, Pardridge WM. 2008. Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer. Pharm. Res. 25(2):400-6
56. Karatas H, Aktas Y, Gursoy-Ozdemir Y, Bodur E, Yemisci M, et al. 2009. A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J. Neurosci. 29(44):13761-69
57. Crowe A, Morgan EH. 1992. Iron and transferrin uptake by brain and cerebrospinal fluid in the rat. Brain Res. 592(1-2):8-16
58. Roberts R, Sandra A, Siek GC, Lucas JJ, Fine RE. 1992. Studies of the mechanism of iron transport across the blood-brain barrier. Ann. Neurol. 32(Suppl. ):S43-50
59. Banks WA, Jaspan JB, Huang W, Kastin AJ. 1997. Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides 18(9):1423-29
60. Bickel U, Yoshikawa T, Pardridge WM. 2001. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev. 46(1-3):247-79
61. Pardridge WM, Kang YS, Buciak JL, Yang J. 1995. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm. Res. 12(6):807-16
62. Boado RJ, Zhang Y, Zhang Y, Pardridge WM. 2007. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol. Bioeng. 96(2):381-91
63. Boado RJ, Zhang Y, Zhang Y, Xia C-F, Wang Y, Pardridge WM. 2008. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol. Bioeng. 99(2):475-84
64. Boado RJ, Pardridge WM. 2010. Genetic engineering of IgG-glucuronidase fusion proteins. J. Drug Target. 18(3):205-11
65. Lu JZ, Boado RJ, Hui EK-W, Zhou Q-H, Pardridge WM. 2011. Expression in CHO cells and pharmacokinetics and brain uptake in the rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein. Biotechnol. Bioeng. 108(8):1954-64
66. Wang D, El-Amouri SS, Dai M, Kuan C-Y, Hui DY, et al. 2013. Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier. Proc. Natl. Acad. Sci. USA 110(8):2999-3004
67. Boado RJ, Hui EK-W, Lu JZ, Pardridge WM. 2009. AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J. Biotechnol. 144(2):135-41
68. Boado RJ, Hui EK-W, Lu JZ, Pardridge WM. 2012. Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor. Drug Metab. Dispos. 40(10):2021-25
69. Kelaita D. 2013. ArmaGen Pipeline. Calabasas, CA: ArmaGen Technol. http://www. armagen. com/pipeline
70. Boado RJ, Zhang Y, Zhang Y, Xia C-F, Pardridge WM. 2007. Fusion antibody for Alzheimers disease with bidirectional transport across the blood-brain barrier and Aβ fibril disaggregation. Bioconjug. Chem. 18(2):447-55
71. Boado RJ, Lu JZ, Hui EK-W, Pardridge WM. 2010. IgG-single chain Fv fusion protein therapeutic for Alzheimers disease: expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey. Biotechnol. Bioeng. 105(3):627-35
72. Boado RJ, Zhang Y, Zhang Y, Wang Y, Pardridge WM. 2008. GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. Biotechnol. Bioeng. 100(2):387-96
73. Boado RJ, Pardridge WM. 2009. Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. Drug Metab. Dispos. 37(12):2299-304
74. Hui EK-W, Boado RJ, Pardridge WM. 2009. Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier. Mol. Pharm. 6(5):1536-43
75. Boado RJ, Hui EK-W, Lu JZ, Zhou Q-H, Pardridge WM. 2010. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. J. Biotechnol. 146(1-2):84-91
76. Boado RJ, Hui EK-W, Lu JZ, Pardridge WM. 2010. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J. Pharmacol. Exp. Ther. 333(3):961-69
77. Boado RJ, Zhang Y, Zhang Y, Wang Y, Pardridge WM. 2008. IgG-paraoxonase-1 fusion protein for targeted drug delivery across the human blood-brain barrier. Mol. Pharm. 5(6):1037-43
78. Boado RJ, Hui EK-W, Lu JZ, Pardridge WM. 2011. CHO cell expression, long-term stability, and primate pharmacokinetics and brain uptake of an IgG-paroxonase-1 fusion protein. Biotechnol. Bioeng. 108(1):186-96
79. Nolan DJ, Ginsberg M, Israely E, Palikuqi B, Poulos MG, et al. 2013. Molecular signatures of tissuespecific microvascular endothelial cell heterogeneity in organ maintenance and regeneration. Dev. Cell 26(2):204-19
80. Demeule M, Poirier J, Jodoin J, Bertrand Y, Desrosiers RR, et al. 2002. High transcytosis of melanotransferrin (P97) across the blood-brain barrier. J. Neurochem. 83(4):924-33
81. Benchenane K, Berezowski V, Ali C, Fernandez-Monreal M, L opez-Atalaya JP, et al. 2005. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation 111(17):2241-49
82. Pan W, Kastin AJ, Zankel TC, van Kerkhof P, Terasaki T, Bu G. 2004. Efficient transfer of receptorassociated protein (RAP) across the blood-brain barrier. J. Cell Sci. 117(Pt. 21):5071-78
83. Chung NS, Wasan KM. 2004. Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv. Drug Deliv. Rev. 56:1315-34
84. Stefansson S, Chappell DA, Argraves KM, Strickland DK, Argraves WS. 1995. Glycoprotein 330/low density lipoprotein receptor-related protein-2 mediates endocytosis of low density lipoproteins via interaction with apolipoprotein B100. J. Biol. Chem. 270(33):19417-21
85. Boren J, Lee I, Zhu W, Arnold K, Taylor S, Innerarity TL. 1998. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. J. Clin. Investig. 101(5):1084-93
86. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, et al. 2009. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J. Control. Release 137(1):78-86
87. Wagner S, Zensi A, Wien SL, Tschickardt SE, Maier W, et al. 2012. Uptake mechanism of ApoEmodified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model. PLOS ONE 7:e32568
88. Spencer B, Marr RA, Gindi R, Potkar R, Michael S, et al. 2011. Peripheral delivery of a CNS targeted, metalo-protease reduces Aβ toxicity in a mouse model of Alzheimers disease. PLOS ONE 6(1):e16575
89. Sorrentino NC, DOrsi L, Sambri I, Nusco E, Monaco C, et al. 2013. A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIa. EMBO Mol. Med. 5(5):675-90
90. Pfeifer A, Kessler T, Yang M, Baranov E, Kootstra N, et al. 2001. Transduction of liver cells by lentiviral vectors: analysis in living animals by fluorescence imaging. Mol. Ther. 3(3):319-22
91. Spencer BJ, Verma IM. 2007. Targeted delivery of proteins across the blood-brain barrier. Proc. Natl. Acad. Sci. USA 104(18):7594-99
92. Herweijer H, Wolff JA. 2007. Gene therapy progress and prospects: hydrodynamic gene delivery. Gene Ther. 14(2):99-107
93. Demeule M, Regina A, Che C, Poirier J, Nguyen T, et al. 2008. Identification and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp. Ther. 324(3):1064-72
94. Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, et al. 1995. LDLreceptor-related protein, a multifunctionalApoE receptor, binds secretedβ-amyloid precursor protein andmediates its degradation. Cell 82(2):331-40
95. Regina A, Demeule M, Che C, Lavallee I, Poirier J, et al. 2008. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br. J. Pharmacol. 155(2):185-97
96. Thomas FC, Taskar K, Rudraraju V, Goda S, Thorsheim HR, et al. 2009. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm. Res. 26(11):2486-94
97. Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, et al. 2012. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol. Cancer Ther. 11(2):308-16
98. Demeule M, Currie J-C, Bertrand Y, Che C, Nguyen T, et al. 2008. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J. Neurochem. 106(4):1534-44
99. Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, et al. 2013. Phase I study of GRN1005 in recurrent malignant glioma. Clin. Cancer Res. 19(6):1567-76
100. Ke W, Shao K, Huang R, Han L, Liu Y, et al. 2009. Gene delivery targeted to the brain using anAngiopepconjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 30(36):6976-85
101. Demeule M, Beaudet N, Regina A, Besserer-Offroy E, Murza A, et al. 2014. Conjugation of a brainpenetrant peptide with neurotensin provides antinociceptive properties. J. Clin. Investig. 124(3):1199-213
102. Stutz CC, Zhang X, Shusta EV. 2014. Combinatorial approaches for the identification of brain drug delivery targets. Curr. Pharm. Des. 20(10):1564-76
103. Muruganandam A, Tanha J, Narang S, Stanimirovic D. 2002. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J. 16(2):240-42
104. Abulrob A, Sprong H, van Bergen en Henegouwen P, Stanimirovic D. 2005. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J. Neurochem. 95(4):1201-14
105. Abulrob A, Stanimirovic D, Muruganandam A. 2007. Blood-brain barrier epitopes and uses thereof. WO Patent. No. CA 2623841 A1
106. Haqqani AS, Caram-Salas N, Ding W, Brunette E, Delaney CE, et al. 2013. Multiplexed evaluation of serum and CSF pharmacokinetics of brain-targeting single-domain antibodies using a NanoLC-SRMILIS method. Mol. Pharm. 10(5):1542-56
107. Kumar P, Wu H, McBride JL, JungK-E, Kim MH, et al. 2007. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448(7149):39-43
108. Lentz TL. 1990. Rabies virus binding to an acetylcholine receptor alpha-subunit peptide. J. Mol. Recognit. 3(2):82-88
109. Liu Y, Guo Y, An S, Kuang Y, He X, et al. 2013. Targeting caspase-3 as dual therapeutic benefits by RNAi facilitating brain-targeted nanoparticles in a rat model of Parkinsons disease. PLOS ONE 8(5):e62905
110. Record M, Subra C, Silvente-Poirot S, Poirot M. 2011. Exosomes as intercellular signalosomes and pharmacological effectors. Biochem. Pharmacol. 81(10):1171-82
111. El Andaloussi S, Lakhal S, Mager I, Wood MJA. 2013. Exosomes for targeted siRNA delivery across biological barriers. Adv. Drug Deliv. Rev. 65(3):391-97
112. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJA. 2011. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29(4):341-45
113. Moos T, Morgan EH. 2001. Restricted transport of anti-transferrin receptor antibody (OX26) through the blood-brain barrier in the rat. J. Neurochem. 79(1):119-29
114. Gosk S, Vermehren C, Storm G, Moos T. 2004. Targeting anti-transferrin receptor antibody (OX26) andOX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J. Cereb. Blood Flow Metab. 24(11):1193-204
115. Paris-Robidas S, Emond V, Tremblay C, Soulet D, Calon F. 2011. In vivo labeling of brain capillary endothelial cells after intravenous injection of monoclonal antibodies targeting the transferrin receptor. Mol. Pharmacol. 80(1):32-39
116. Alata W, Paris-Robidas S, Emond V, Bourasset F, Calon F. 2014. Brain uptake of a fluorescent vector targeting the transferrin receptor: A novel application of in situ brain perfusion. Mol. Pharm. 11(1):243-53
117. Manich G, Cabezon I, del Valle J, Duran-Vilaregut J, Camins A, et al. 2013. Study of the transcytosis of an anti-transferrin receptor antibody with a Fab cargo across the blood-brain barrier in mice. Eur. J. Pharm. Sci. 49(4):556-64
118. Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, et al. 2011. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci. Transl. Med. 3(84):84ra43
119. Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, et al. 2012. Gantenerumab: A novel human anti- Aβ antibody demonstrates sustained cerebral amyloid-βbinding and elicits cell-mediated removal of human amyloid-β. J. Alzheimers Dis. 28(1):49-69
120. Wiley DT, Webster P, Gale A, Davis ME. 2013. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc. Natl. Acad. Sci. USA 110(21):8662-67
121. Mayle KM, Le AM, Kamei DT. 2012. The intracellular trafficking pathway of transferrin. Biochim. Biophys. Acta 1820(3):264-81
122. Widera A, Norouziyan F, Shen W-C. 2003. Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Adv. Drug Deliv. Rev. 55(11):1439-66
123. Muro S. 2003. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J. Cell Sci. 116(8):1599-609
124. Papademetriou J, Garnacho C, Serrano D, Bhowmick T, Schuchman EH, Muro S. 2013. Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor. J. Inherit. Metab. Dis. 36(3):467-77
125. Jevnikar AM, Wuthrich RP, Takei F, Xu HW, Brennan DC, et al. 1990. Differing regulation and function of ICAM-1 and class II antigens on renal tubular cells. Kidney Int. 38(3):417-25